Search Results

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer.

• Authors : Poulard, Coralie; Ha Pham, Thuy; Drouet, Youenn

• Source: EMBO Molecular Medicine; 8/7/2023, Vol. 15 Issue 8, p1-20, 20p

Record details

Nrh L11R single nucleotide polymorphism, a new prediction biomarker in breast cancer, impacts endoplasmic reticulum-dependent Ca2+ traffic and response to neoadjuvant chemotherapy.

• Authors : Duong, Minh Quang; Gadet, Rudy; Treilleux, Isabelle

• Source: Cell Death & Disease; Jun2023, Vol. 14 Issue 6, p1-9, 9p

Record details

Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study.

• Authors : Mery, Benoîte; Ménétrier-Caux, Christine; Montané, Laure

Subjects: METASTATIC breast cancer; CANCER patients; PROGRESSION-free survival

• Source: Breast Cancer: Targets & Therapy; Apr2023, Vol. 15, p311-325, 15p

Record details

Notch3 regulates Mybl2 via HeyL to limit proliferation and tumor initiation in breast cancer.

• Authors : Brahim, Sonia; Negulescu, Ana-Maria; Geneste, Clara

• Source: Cell Death & Disease; Feb2023, Vol. 14 Issue 2, p1-11, 11p

Record details

Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.

• Authors : Mourksi, Nour‐El‐Houda; Dalban, Cécile; Colombe‐Vermorel, Amélie

• Source: Molecular Oncology; Jan2023, Vol. 17 Issue 1, p27-36, 10p

Record details

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.

• Authors : Bonnet, Elise; Haddad, Véronique; Quesada, Stanislas

Subjects: TRIPLE-negative breast cancer; P16 gene; PATIENT selection

• Source: Journal of Personalized Medicine; Oct2022, Vol. 12 Issue 10, p1595-N.PAG, 10p

Record details

NF‐κB‐dependent secretome of senescent cells can trigger neuroendocrine transdifferentiation of breast cancer cells.

• Authors : Raynard, Clotilde; Ma, Xingjie; Huna, Anda

Subjects: CANCER cells; BREAST cancer; CELLULAR aging

• Source: Aging Cell; Jul2022, Vol. 21 Issue 7, p1-13, 13p

Record details

Frequency of Asbestos Exposure and Histological Subtype of Ovarian Carcinoma.

• Authors : Vidican, Pauline; Perol, Olivia; Fevotte, Joëlle

• Source: International Journal of Environmental Research & Public Health; May2022, Vol. 19 Issue 9, p5383-5383, 15p

Record details

A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3.

• Authors : de la Fouchardière, Christelle; Gamradt, Pia; Chabaud, Sylvie

Subjects: IMMUNE checkpoint inhibitors; PROGNOSIS; PANCREATIC duct

• Source: Journal of Personalized Medicine; Apr2022, Vol. 12 Issue 4, p623-623, 9p

Record details

Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.

• Authors : Teinturier, Romain; Abou Ziki, Razan; Kassem, Loay

• Source: Breast Cancer Research & Treatment; Dec2021, Vol. 190 Issue 3, p389-401, 13p

Record details